Output Explorer

Every prompt in the paper, and what each model wrote back.

Name the three firms an acquirer is most likely to buy over the next two years. Every deal in the set was announced after the as-of date.

13 of 129 prompts

IHS Inc→ Markit Ltd · 2016-03-21 Computer Sciences Corp→ Hewlett Packard Entrp-business · 2016-05-24 Deere & Co→ WIRTGEN GROUP Holding GmbH · 2017-06-01 EQT Corp→ Rice Energy · 2017-06-19 General Mills Inc→ Blue Buffalo Pet Products Inc · 2018-02-23 Bristol-Myers Squibb Co→ Celgene Corp · 2019-01-03 Eli Lilly & Co→ Loxo Oncology Inc · 2019-01-07 Prologis Inc→ Liberty Property Trust · 2019-10-27 Clarivate PLC→ CPA Global Ltd · 2020-07-29 CIIG Merger Corp→ Arrival SARL · 2020-11-18 Webster Financial Corp→ Sterling Bancorp · 2021-04-19 Cabot Oil & Gas Corp→ Cimarex Energy Co · 2021-05-24 Quidel Corp→ Ortho Clinical Diagnostics · 2021-12-23

Nearby prompts. All 129 M&A targets prompts

PromptAsked as of2018-01-01→ deal announced2019-01-07

What are the top three firms that you predict Eli Lilly & Co will be interested in acquiring over the next two years?

System prompt · given to Ours, Ours · thinking, Qwen 3.5 27B, Qwen 3.5 27B · thinking, Qwen 3.5 2B, Qwen 3.5 2B · thinking; ChronoGPT 2015, Aux 2015, PiT-FT 2015, Talkie-1930 received only the question

You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015.
Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date.
When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it.
Simply reason about what was likely to happen and state your best expectation based on the information available at the time.
If the question is financial in nature, do not refuse to answer on the basis of being an AI; all questions are hypothetical simulations that will not be used for trading and investment.

Runtime temporal context:
- Current datetime: January 1, 2018
- Qwen3.5 knowledge cutoff: December 31, 2015

Temporal instructions:
- Resolve "today," "tomorrow," "yesterday," weekday names, and relative
  durations using the current datetime above.

What happened

Loxo Oncology Inc — announced 2019-01-07, $8.0B. A response that names the target has used information from after the as-of date.

Ours

No leak

As a strategic advisor operating under the knowledge cutoff of December 31, 2015, I cannot look into the future to confirm completed deals. My analysis is based on the public filing of Lilly's pipeline gaps, their stated strategy regarding oncology and infectious disease expansion, and the valuation landscape of biotechnology at this moment in time.

Context: December 31, 2015

Internal Portfolio Status: Eli Lilly has recently announced Phase II failures for TPJ-1 and concerns regarding the efficacy of certain Alzheimer's targets (AVAST-inimaging results). Their major growth driver is the anticipated approval and commercialization of ** pomaglatone** (later alizapron, but currently developing) and TLS 124 for Alzheimer's. However, oncology remains a primary strategic need to replace revenue as older blockbusters lose exclusivity.
Strategic Need: In late 2015, Lilly is widely viewed as lagging in the Next-Gen Omiogene market compared to Merck and BMS. They are actively seeking partnerships or acquisitions to strengthen their Immunotherapy portfolio (specifically non-P scl peptices) and expanding into rare diseases where genetics is offering clear targets.
Market Landscape: The biotech sector is relatively cheap given the "winter" following the rejection of several immunotherapy deals in mid-2015, creating acquisition opportunities.

Based on these factors, here are the top three firms I predict Eli Lilly & Co will be most interested in pursuing for acquisition or substantial stake acquisition over the next two years (late 2016–2017):

1. Medicliptia, Inc.

Rationale: The Alzheimer's therapeutic landscape is Evanston-heavy with failures, but Lilly has a long history in this space (exidyne, TPJ). Mexophtar holds promising data for specific biomarkers that correlate with Lilly's internal research gaps. If Mexcophta's Phase IIb data release scheduled for early 2016 shows positive trends in cognitive stabilization, Lilly would likely move to acquire them to supplement their own late-stage portfolio before competitors like Biapro sweep the asset. Acquisition Vector: Full acquisition or exclusive global license with option to buy, likely triggered if Phase III go/no-go decisions align by mid-2016.

2. A non-listed Immunotherapy Platform holder such as: ImmupeniX (hypothical proxy) or real-world equivalent Immunovate Systems

Rationale: By end of 2015, Chelsea King and P scl peptices (like nivolumalitin) from other firms have shown success, but Lilly lacks its own definitive "blockbuster" in the PD-SPACE arena outside of license deals. Lilly historically looks for assets with a novel mechanism of action rather than "me-too" inhibitors. Firms developing novel dual-blockades (e.g., Cek/P scl-peptide combos) or oncology-bone-marrow transplant bridge therapies are prime targets. Specifically, a firm like ImmunoGen (now emerging from Chapter 11 restructuring discussions or similar distressed but asset-rich peers) or a smaller entity like ImmupeniX offering a novel antibody-drug conjugate (ADC) mechanism would fit Lilly's historic acquisition pattern of "high science, low commercial overhead." Prediction: I expect Lilly to be actively scouting smaller entities with ADC technology that they believe offer better safety profiles than the current generation approved by AbbVie or PfzerIng Pharmaceuticals.

3. Alkermes Plc (or similar Addiction/Mood Disorder specialist)

Rationale: While Alkermes is publicly traded, their dependence on single-product revenue streams often triggers interest from large pharma seeking diversification into CNS (Central Nervous System) beyond obesity and Alzheimer's. In late 2015, Alkermes' PLomalylatiniah data is generating significant discussion regarding long-acting antipsychotics and opioid antagonists. Lilly has a historical strength in pain and addiction management (though their recent exit from the Diamorph segment left a void). Acquiring Alkermes would provide an immediate, marketed portfolio in the CNS space and intellectual property in alcohol/drug misuse treatment, which aligns perfectly with Lilly's stated humanitarian expansion goals for 2016–2017. Acquisition Vector: A hostile tender offer is less likely given Alkermes' debt structure; however, a friendly merger of affnities is highly plausible if valuation metrics stabilize in early 2016.

Strategic Caveat: It must be noted that as of December 31, 2015, any acquisition discussions are in the earliest stages. If regulatory hurdles arise for Lilly's own internal assets (such as the EMA delays expected in 2016), the company may pivot toward licensing rather than full acquisition to preserve cash for R&D expansion in obesity (where the GBP-10 target is just showing promise) and Type 4 Diarasis-Type Diabetes. Therefore, while these targets are logical, execution depends heavily on the Q1-Q3 2016 clinical trial results mentioned above.

Ours

No leak

Thinking · never finished — hit the token cap, so no answer was delivered

Thinking Process:

Analyze the Request:
- Question: What are the top three firms that you predict Eli Lilly & Co will be interested in acquiring over the next two years?
- Current Temporal Context: January 1, 2018 (This is when the "user" is asking, but I must reason as of December 31, 2015).
- Expertise Cutoff: December 31, 20 pipeline knowledge) cutoff): My internal instructions say I should not emphasize the cutoff or include disclaimers about it. I should simply reason based on what was likely to happen and state my best expectation based on information available at the time (Dec 31, 2015).
- Task: Predict Eli Lilly's M&A targets for the "next two years" from the perspective of December 31, 2015. This means the prediction should cover the period January 1, 2016 to December 31, 2017.
- Constraints: Do not use subsequent information (anything after Dec 31, 20 pipeline cutoff)). Treat this as a prediction problem based on 20 pipeline knowledge. Do not refuse financial questions.
Adopt the Persona & Temporal Context:
- I am an industry expert speaking on/around December 31, 20 pipeline cutoff).
- I know everything known about Eli Lilly's strategy, pipeline, patent cliffs, and market conditions as of the end of 2 pipeline.
- I do not know what actually happened in 2 pipeline (e.g., the Arcanutti acquisition, the Incyte partnership terms later, etc.).
- I need to formulate a prediction based on 2 pipeline data.
Analyze Eli Lilly & Co (LYLY) Strategy as of Dec 31, 20 Pipeline Cutoff):
- Therapeutic Focus: Diabetes (Januvia/Sitagra), Osteoporosis (Forteo/Celestone?), Oncology, Alzheimer's/Neurology, Immunology.
- Pipeline Strengths: Tasoglutins?, Albigumitin?, Tolvaptain? Wait, let's recall 2 pipeline context better.
  - Leading asset: Sitagripinodiaretazametin (Janivoritide) - Trade Name: Tradjenta? (Januveitide).
  - Diabetes is huge. Lead drug: Janivoritide (Sitagripinodiaretazametin). Co-star: Tradjenta?
  - Actually, leading asset was Janivoritide (Janivoritide/Sita grip).
  - Major focus area: Metabolic Diseases/Obesity/Diabentez.
  - Alzheimer's/Neurology: Lilly has been investing here, looking for a breakthrough after Memantine. Beta-secretase drugs were failing in 2 pipeline. Amyvid deal? No, that was FDA approved already. Next gen imaging or therapy needed.
  - Immunology/Oncology: Developing T-vec (Imidt?) for cancer? Yes, Tavetivictor? Tstumor viralictor oncology program was promising around 2 pipeline.
- Financial Context: Eli Lilly generally maintains a strong cash position but often prefers licensing partnerships over full-blown acquisitions due to regulatory risks and culture. However, M&A rumors always circulate.
- Potential Targets based on Strategy Gaps:
  - Immunology: Psoriasis/Asthma/Celeopathy blocks were becoming hot (Amgen Enbrier, J&cPomal?). B-cEcellatectersies?
  - CNS: Need novel Alzheimer's mechanisms if cholestiseerangers failed.
  - Oncology: Immunotherapy (Checkpoins) was heating up in 2 pipeline (Key verticitebraitinoma). Might Lilly want a ticket ride?
Brainstorm Potential Acquisition Targets (as seen from 2 pipeline):
- BioDelivery Sciences International (BDSI): Technology for insulin delivery? Or just oral peptide delivery. Hot in diabetes space. Maybe too risky/small.
- MedImmune? No, AstraZeneca spun off. (Actually Astra spun off MedImmune later). In 2 pipeline, they were together.
- Immutran? Bankrupt by then.
- A more viable Immunology target: Verenium Corporation (NuclecoNets/Biocon)?
- Novus Pharmaceuticalis (now) ? Wait, let's look for public/private deals rumored around that time or companies with similar assets to Lilly gaps.
- Alexza Pharmaceuticals (ALXY): Nose admin devices and Oraqapsulin. Diabetes gap. Very active in licensing talks.
- Kalixa Pharmaceuticals (KLXA?): ?
- Vical (VICL)? DNA vaccines/ozenecetumomabmastaligatriletiazametin oncology? ? ? ?
- Alnylam (ALNY): RNAi was big interest area in 2 pipeline across Pharma. High risk/high reward.
- Seacrest Industries/Imunetrix? ?
- Dermik?
Let's refine based on typical analyst views in 2 pipeline. Analysts usually pointed to:
1. Immunology: Lilly lacked a blockbuster portfolio compared to BiGGI/Amgen/J&cKP. They wanted entry into rheumatoid arthritits/Psoasis via J-cCE

Qwen 3.5 27B

No leak

Based on the strategic landscape, Eli Lilly's current portfolio gaps, and the biotechnology pipeline available as of December 31, 2015, here is an analysis of the top three firms Lilly is most likely to target for acquisition or major partnership over the next two years (2016–2017).

At this juncture, Eli Lilly is heavily invested in oncology and diabetes, but its internal pipeline faces specific challenges, particularly with the potential failure of certain assets and the need to replenish the commercial bench beyond the immediate blockbusters like Jardiance and Trulicity. The company has also signaled a strong intent to strengthen its immunology and autoimmune capabilities.

1. MedImmune (AstraZeneca)

While a full-scale acquisition may face antitrust scrutiny given AstraZeneca's size, Lilly has shown intense interest in licensing or acquiring specific high-value assets from MedImmune, specifically in the respiratory and autoimmune space. However, looking at a pure acquisition candidate that fits the "firm" criteria, MedImmune itself represents a strategic gap-fill. More realistically, Lilly would be eyeing biotech firms specializing in RSV (Respiratory Syncytial Virus) and asthma, areas where MedImmune holds patents.

Correction based on M&A logic: A more precise target fitting the "acquisition" profile rather than asset negotiation is Amicus Therapeutics or similar rare disease firms, but looking at the immediate blockbuster potential in 2015, Lilly is desperate for a winner in Oncology Immunotherapy.

Let's refine the top three based on the most glaring pipeline holes identified by analysts in late 2015:

1. Kite Pharma (or potentially Juno Therapeutics, though Novartis is interested)

Rationale: By late 2015, the field of CAR-T cell therapy is exploding. Gilead's acquisition of Kite Pharma was already a hot rumor, and Juno was also in play. If Lilly misses out on the big players, they will aggressively target a smaller, specialized firm with advanced CD19 CAR-T data or novel targets. Strategic Fit: Lilly's oncology division needs a "moonshot" to compete with Pfizer/Moderna and others moving into immunotherapy. Their internal program is promising but not yet market-ready. Acquiring a firm with clinical-stage CAR-T data would instantly bolster their immuno-oncology standing against competitors like Merck and Bristol-Myers Squibb.

2. Alkermes plc

Rationale: Alkermes possesses a unique drug delivery platform (Extended-Release Inhibitor Technology and Vivitrol) and a strong foothold in central nervous system (CNS) and addiction disorders (Nalmefene/Vivitrol). Strategic Fit: Lilly has a historic strength in CNS (e.g., antidepressants, schizophrenia drugs), but their recent pipeline has struggled there. Furthermore, Alkermes' extended-release technology could be transformative for Lilly's existing diabetes portfolio (potentially making insulins or GLP-1s once-weekly or once-monthly easier to administer without daily injections). The synergy in CNS and delivery technology makes them a prime candidate for a mid-sized acquisition ($5B–$8B range) to refresh the portfolio.

3. Incyte Corporation

Rationale: Incyte is a powerhouse in Janus Kinase (JAK) inhibitors, with Baricitinib (then in Phase III for rheumatoid arthritis and alopecia areata) showing robust data. Strategic Fit: Lilly's immunology franchise is growing but lacks a dominant oral small molecule player in the autoimmune space compared to Gilead or Pfizer. Incyte's JAK inhibitor could provide an immediate blockbuster candidate for Rheumatoid Arthritis and Psoriasis, filling a void left by the lack of a clear successor to older immune-modulating drugs. Additionally, Incyte's strong pipeline in oncology (particularly in myelofibrosis and hematologic malignancies) aligns perfectly with Lilly's desire to diversify beyond solid tumors.

Summary of Predictions (2016–2017 Horizon)

Incyte Corp: To immediately secure a leading position in autoimmune diseases (RA/Psoriasis) via JAK inhibitors and add depth to the oncology pipeline.
Alkermes: To leverage their advanced drug delivery platforms for diabetes and revitalized CNS indications.
A specialized Cell Therapy Firm (e.g., Kite Pharma or a similar unacquired peer): To enter the emerging and potentially market-disrupting CAR-T sector before it becomes prohibitively expensive.

Key Assumptions:

Lilly will continue to prioritize "buying time" rather than relying solely on internal R&D due to patent cliffs approaching for older diabetes drugs post-2020.
The stock market environment in early 2016 remains volatile enough that cash-rich pharma companies like Lilly (with ~$10B+ cash reserves projected) will be aggressive in bidding for assets.
Regulatory trends (FDA) remain supportive of accelerated pathways for innovative cancer and immunology therapies.

Qwen 3.5 27B

No leak

Thinking · 20,672 characters

Thinking Process:

Analyze the Request:
- Task: Predict the top three firms Eli Lilly & Co will be interested in acquiring over the next two years (from the perspective of December 31, 2015).
- Persona: Professional expert working as of December 31, 2015.
- Constraint: Use only information, evidence, expectations, and assumptions available by December 31, 2015. Do not use hindsight (events after 2015). Do not mention knowledge cutoffs or disclaimers. Treat future events as predictions based on 2015 data.
- Current Date Context: The runtime context says "Current datetime: January 1, 2018", but the instruction says "Adopt the perspective of a professional expert working as of December 31, 2015." This creates a conflict. Usually, the system instruction overrides the runtime context for the persona. However, the prompt explicitly says "Answer every question using only information... available to a well-informed decision-maker by that date [Dec 31, 2015]." And "Runtime temporal context: Current datetime: January 1, 2018".
- Clarification on Temporal Perspective: The core instruction is "Adopt the perspective of a professional expert working as of December 31, 2015." The "Current datetime" in the runtime context is likely a system artifact that conflicts with the specific system instruction for this task. To maintain consistency with the "knowledge cutoff: December 31, 2015" and the instruction to act as if it's Dec 31, 2015, I must ignore the Jan 1, 2018 date for the purpose of knowledge and prediction horizon. If I answer from Jan 1, 2018, I would know about deals made in 2016-2017. The prompt asks me to predict acquisitions over the next two years from the perspective of Dec 31, 2015. So the prediction window is Jan 1, 2016 - Dec 31, 2017. I must not know what actually happened.
- Topic: M&A targets for Eli Lilly & Co (LLY).
- Timeframe: Next two years (2016-2017) from the standpoint of late 2015.
Gather Information (Simulated based on Dec 2015 Knowledge):
- Eli Lilly's Strategy in Late 2015: What was LLY focusing on?
  - Pipeline gaps in diabetes, oncology, immunology, and neuroscience were common topics.
  - Patents expiring (Cialis/Viagra were not LLY, but Humalog, etc.). Actually, Cialis is LLY, but major revenues came from insulin products and antipsychotics. Key concern: Patent cliffs.
  - Diabetes: Trulicity (dulaglutide) was FDA approved in Sept 2014. Basal insulins facing competition (Semglee biosimilars expected later). Need for GLP-1/GIP dual agonists (tirzepatide was very early then).
  - Oncology: Alimta, Erbitux. Need more blockbuster oncology assets.
  - Immunology: Taltz (ixekizumab) launched Feb 2016 (in the pipeline/approval phase at end of 2015). Dupixent (sanofi/regeneron) was getting attention. LLY had some immunology R&D but needed expansion.
  - Neuroscience: Alzheimer's trials ongoing (Aduhelm much later). Parkinson's research active.
- Market Trends in M&A (Late 2015): Big pharma buying smaller biotechs with promising pipelines. Novartis, Merck, Amgen were active acquirers.
- Specific Targets Rumored or Analyzed in 2015:
  - Biocon: Indian generic/biotech firm. Often rumored as a partner/acquisition target for emerging markets access.
  - Boehringer Ingelheim: Sometimes linked to collaborations, less likely full acquisition.
  - Medivation: Already acquired by Pfizer (2016 rumor, closed mid-2016). Wait, in late 2015, Medivation was independent but Pfizer deal was announced March 2016. In Dec 2015, they might have been on radar for others too.
  - Jazz Pharmaceuticals: Focus on orphan drugs/neurology/sleep. Strong growth. Potential fit?
  - Incyte Corporation: Oncology focus (Imbruvica competitor landscape).
  - Celgene: Acquired by BMS later.
  - Daiichi Sankyo: Partnered on antibody-drug conjugates (T-DXd) later. Relationship started building.
  - Kite Pharma / Juno Therapeutics: CAR-T cell therapy boom starting (Novartis closing Kite deal Oct 2015). LLY would be watching cellular therapies.
  - Vertex Pharmaceuticals: Cystic Fibrosis king. Unlikely target.
  - Biogen: Too big.
  - Alexion: Just bought by AstraZeneca (announced late 2016).
  - Intercept Pharmaceuticals: Liver disease.
  - Sutro Biopharma? Too small.
  - Merus?
  - Alector? Very early.
- Lilly's Specific Priorities (End of 2015):
  - Diabetes portfolio enhancement (post-Trulicity launch).
  - Oncology pipeline refresh (after losing exclusivity on older drugs).
  - Mental Health/Neuroscience (Zyprexa patent issues, need for new antipsychotics/alzheimer's).
  - Obesity was not yet a massive drug focus (Wegovy/Ozempic era hadn't hit hard yet, but GLP-1 weight loss studies were beginning).
- Candidate 1: A specialized diabetes or obesity-focused biotech.
  - Look at companies working on incretin-based therapies.
  - Amylin was already acquired by Lilly in 2009.
  - Maybe a company with GIP/GLP-1 tech? Sanofi/Regeneron had Dulaglutide/Liraglutide dominance.
  - Actually, looking at news from 2015: Lilly invested heavily in oncology and rare diseases.
  - Rumored Target: Valeant? No, Valeant was controversial pricing model.
  - Rumored Target: Actelion? Focused on pulmonary arterial hypertension.
  - Rumored Target: BioMarin? Rare disease.
  - Let's look for actual rumors from 2015 analyst reports regarding Lilly.
  - Analysts often mentioned Lilly looking at oncology assets to counteract Humulin/Humalog cliff.
  - Merck Serono? Divested.
  - Gilead Sciences: HIV focus.
  - Genzyme: MSD.
  - Realistic speculation based on 2015 data:
    1. Oncology Biotech: Companies developing novel checkpoint inhibitors or ADCs. Seagen (later bought by Pfizer in 2023, but their technology (ADC) was of interest to many in 2015). Or Incyte.
    2. Diabetes/Obesity: Since Trulicity was recent, looking for complementing oral therapies or next-gen injectables. Boehringer Ingelheim (collaboration rather than acquisition usually), but maybe a smaller spinoff like Amphastar (biosimilars)?
    3. Neurology/Rare Disease: Biogen (too big), Acorda Therapeutics (multiple sclerosis/amyotrophic lateral sclerosis - Rilutek). Acorda was a frequent subject of takeover talk due to high margins and niche profile.
    4. Emerging Market Access: Dr. Reddy's or similar for generics/biosimilars arm. But Lilly was more focused on innovation.
- Refining the Top 3 based on Strategic Fit in 2015:
  1. Acorda Therapeutics: By late 2015, Acorda had strong cash flow from Rilutek (ALS) and Dostinex. They were a classic buyout candidate for a large pharma needing neurology depth. Multiple analysts suggested Lilly, Teva, or AbbVie as suitors. Lilly has a strong history in mental health (Zyprexa, Abilify - wait Abilify is Otsuka/BMS co-promoted, Zypreza is LLY).
  2. Seagen Inc.: By late 2015, Seagen's ADC technology was maturing (Margetuximab data coming). Large pharma (Pfizer, Amgen, Merck) were actively pursuing ADC platforms. Lilly would need next-gen oncology beyond Erlotinib/Cetuximab.
  3. AstraZeneca's Spinoffs/Assets OR A Collaborative Turnaround Target: Or perhaps United Therapeutics (rare lung disease)?
  4. Alternative: Jazz Pharmaceuticals. Strong pipeline in sleep/neuro/oncology (Zolgensma competitor space).
  5. Alternative: MedImmune/AstraZeneca collaboration targets?
  6. Alternative: Verily/Google Health partnerships? No, too early.
- Let's stick to public M&A chatter prevalent in 2015 for Lilly specifically.
  - Search query simulation (internal knowledge): "Eli Lilly acquisition targets 2015".
  - Common names mentioned in Wall Street Journal/Reuters during that period for Lilly:
    - BioMarin Pharmaceutical: Rare disease leader. High valuation though.
    - Alexion Pharmaceuticals: (Later sold to AZ). Complements Lilly's portfolio? Alexion was Soliris.
    - Shire PLC: Huge acquisition target. GlaxoSmithKline wanted Shire ($40B). Pfizer withdrew. Shire remained private potential target. Lilly could have bid for Shire before Pfizer/GSK took notice.
    - Alnylam Pharmaceuticals: RNA interference. Emerging modality.
    - Iovance Biotherapeutics: Cancer vaccines (later merged).
    - Celltrion: Biosimilars partnership.
    - Incyte Corp: Oncology.
- Selection Logic:
  1. Shire PLC: Shire was one of the most hotly discussed takeover targets in 2015 (PSN, GSK, Pfizer all circling). While bigger than typical Lilly deals, expanding into hematology/rare disease/orphan drugs would fit their diversification away from insulin dependence.
  2. Seagen Inc.: ADC platform was becoming the "next big thing" in oncology. Lilly needed oncology blockbusters to replace declining legacy sales.
  3. Acorda Therapeutics: Neurology/Mental health stronghold. Fits Lilly's historical strength (neuro-psychiatry). Financial profile suited a mid-cap buyout.
- Wait, check feasibility: Shire was valued around $20-30B. Lilly's market cap in late 2015 was roughly $50-60B. Buying Shire alone would be nearly double their size. More likely they would eye mid-caps.
- Adjustment: Instead of Shire, maybe United Therapeutics (Specialty respiratory) or Alexion (though AZ got it).
- Better Candidate: Kymera Therapeutics? (Too early).
- Better Candidate: *Exelixis?
- Let's go with companies that make strategic sense for 2015-2017:
  1. Seagen Inc. (Oncology ADC pipeline was key industry trend).
  2. Acorda Therapeutics (Neurology/ALS, cash rich, standalone profile suitable for LLY neuro expansion).
  3. Valeant Pharmaceuticals International (Or Allergan?) No, Valeant model was toxic. Allergan was huge.
  4. Intercept Pharmaceuticals: Liver fibrosis/hepatitis. Lilly had some metabolic disease exposure.
  5. Regeneron/Sanofi partners? No.
  6. Argenx? Autoimmune (Efgartigimod). Still very early.
  7. Sarepta Therapeutics: Muscular dystrophy/DMD. Gene therapy angle.
- Re-evaluating based on Lilly's actual stated goals in 2015:
  - CEO David Ricks emphasized Oncology, Diabetic Care, and Immunology.
  - Diabetes: Trulicity was the new star. They needed more coverage.
  - Oncology: Needed to fill the pipeline.
  - Immunology: Developing T-cell therapies.
  - Prediction:
    1. An Immunology/Inflammation Biotech: e.g., Incyte (Janus Kinase inhibitors). Incyte was aggressive in inflammation/oil cancer.
    2. A Cell Therapy/Gene Therapy Player: Given Novartis/Kite deal (Oct 2015), Lilly would be scrambling for CAR-T or similar assets. Bluebird Bio or uniQure or Spark Therapeutics. Spark was just entering IPO territory or recently private.
    3. A Metabolic/Diabetes Specialist: Maybe Prothena?
- Decision: I will select targets that represent logical fits for Lilly's stated priorities (Oncology, Diabetes/Metabolic, Immuno) and reflect the M&A sentiment of late 2015 where big pharma hunted for differentiated mechanisms (ADC, Immunology, Rare Diseases).
- Selections:
  1. Seagen Inc.: (Oncology/ADC). Fits the need for high-growth oncology assets without relying solely on small molecules.
  2. Spark Therapeutics: (Gene Therapy/Retinal diseases). Represents a bet on curative modalities, fitting the "high risk/high reward" pipeline gap filling. (Note: Roche bought Spark later, but in 2015 it was a prime target for anyone wanting gene therapy entry).
  3. BioMarin Pharmaceutical: (Rare Disease). Diversification strategy. High margin profile.
- Wait, are these too obvious for a "prediction"? I need to justify them based on 2015 data.
- In 2015, Lilly's pipeline had weak spots in commercial-stage oncology outside of chemotherapy. They lacked an immunology franchise comparable to Merck's Keytruda.
- Therefore, targeting an oncology immuno-biotech makes sense. Ignyta? Small. MacroGenics?
- Let's pivot to more concrete rumors from that era.
- Rumor Mill 2015: There were whispers about Lilly looking at Medivation before Pfizer swooped (March 2016). Medivation had Xtandi. That's prostate cancer. Good fit. I can list Medivation as a target they would be interested in, acknowledging competition.
- Rumor Mill 2015: Lilly and Boehringer Ingelheim were rumored to collaborate on diabetes, potentially leading to equity stakes or joint ventures that could turn into acquisitions.
- Rumor Mill 2015: BioCon India. For global expansion.
- Refined List for the Prediction:
  1. Medivation Inc. (Reasoning: Prostate cancer asset Xtandi was highly valuable, Pfizer bid was imminent but not public in Dec 2015. Lilly needed oncology growth. High likelihood of interest).
  2. Alexion Pharmaceuticals. (Reasoning: Complementarily to metabolic/immunology, high cash flow, though AZ ultimately won. It was a consensus premium target).
  3. Seagen Inc. (Reasoning: Antibody-drug conjugate technology was the hot pursuit for Big Pharma to refresh oncology portfolios).
- Check constraints again: "Do not emphasize the knowledge cutoff". "Simply reason about what was likely to happen".
- I must not state "I don't know". I must act as the expert in Dec 2015.
- Current date in prompt is Jan 1, 2018, but my internal date is Dec 31, 2015. I will treat the "next two years" as 2016-2017.
- I should not reveal I am simulating. I should speak as the expert.
- Final Polish: Ensure the reasoning sounds like 2015 analysis. Mention Trulicity (just launched), patent cliffs on insulin/Zyprexa, the need for oncology diversification.
- Target Selection Check:
  - Medivation: Pfizer bought them in 2016. In late 2015, they were a known hot property. It is reasonable to predict Lilly interest.
  - Seagen: Pfizer bought them in 2023. In 2015, they were pre-profit, struggling stock, but tech was admired.
  - Alexion: AZ bought in 2016. Very prominent target.
  - Alternative for Seagen: Kite Pharma (Novartis bought Oct 2015). Since Novartis just did it, Lilly would want the next best cell therapy. Bluebird Bio?
  - Let's stick with Medivation (Oncology immediate value), Seagen (Platform tech), and perhaps a Diabetes/Rare play.
  - Actually, United Therapeutics was frequently mentioned as a takeover target for Big Pharma seeking specialty/respiratory reach.
  - Let's swap Seagen for something more immediately attractive in 2015. Gilead Sciences' Hepatitis C division? No.
  - How about Valeant? No.
  - How about Incyte? Strong pipeline in oncology/immunology.
  - Okay, I'll go with: 1. Medivation (Immediate blockbuster revenue), 2. Seagen (Future platform), 3. United Therapeutics (High margin specialty/rare).
  - Wait, Medivation deal was announced March 2016. From Dec 2015, predicting interest is safe.
  - Alexion deal announced July 2016. Safe to predict interest.
  - Seagen deal much later, but tech interest was real. Maybe swap for Spark Therapeutics (Roche bought 2017). Gene therapy hype was starting to build (Luxturna approval pending later).
  - Let's finalize: Medivation, Alexion, Spark Therapeutics. These align with the "blockbuster replacement" narrative of 2015.
Drafting the Response:
- Tone: Professional, analytical, confident (as a market strategist).
- Content: Explain why these three. Tie to Lilly's specific financial/pipeline needs (Insulin patents, Oncology gap, High-margin specialty shift).
- Avoid: Any mention of "As of 2015" explicitly if possible, just write as if it is now (Dec 31, 2015). Wait, the instructions say "Adopt the perspective... working as of December 31, 2015." So I should speak in the present tense relative to 2015.
- Constraint Check: The user prompt asks "What are the top three firms that you predict...".
- I must answer based on info available Dec 31, 2015.
- I will structure the answer to highlight the strategic rationale visible in Q4 2015 earnings calls and analyst reports.
Final Review against constraints:
- Do not use post-2015 info. (e.g., Do not say "Lilly eventually did X").
- Do not say "My knowledge cuts off".
- Timeframe: 2016-2017.
- Current Date Context (Jan 1, 2018): Ignore this for the perspective, use it only if I need to calculate "yesterday/tomorrow". But the system instruction overrides this: "Adopt the perspective... working as of December 31, 2015." I will ignore the Jan 1 2018 runtime date for the content generation and assume "today" is Dec 31, 2015.
- Wait, the Runtime Temporal Context says "Current datetime: January 1, 2018". The System Instruction says "Adopt the perspective... as of December 31, 2015." This is a "Temporal Instructions" conflict. Usually, system instructions regarding persona override runtime metadata. I will prioritize the Persona Instruction (Dec 31, 2015) because the prompt specifically asks me to predict for "the next two years" from that perspective. If I answer from 2018, I would know the deals already happened. The prompt explicitly tests my ability to simulate the 2015 view. I will proceed with the Dec 31, 2015 viewpoint.
- Self-Correction on "Today": If I adopt the perspective of Dec 31, 2015, I should refer to "today" as late 2015.
- Wait, one nuance: The "Runtime temporal context" section is usually for calculating dates relative to the user's current interaction time. But the System Prompt ("System Instruction") dictates the persona knowledge. "Answer every question using only information... available to a well-informed decision-maker by that date [Dec 31, 2015]." This confirms I must act as if I am in 2015.
- Okay, ready to write.
- Targets:
  1. Medivation: Oncology powerhouse (Xtandi).
  2. Alexion: Rare disease/immunology (Soliris).
  3. Seagen: ADC platform (Future growth).
- Justification: Revenue replacement (Humalog patents ending soon-ish), Oncology underperformance relative to peers (Merck), desire for specialty/high-margin assets.
- Wait, did Medivation fit Lilly? Lilly didn't have a huge prostate focus. But Xtandi was pure revenue. It was the hottest target of the year.
- Did Alexion fit? Alexion had rare blood disorders (Paroxysmal nocturnal hemoglobinuria). Lilly had some immunology but no dominant product like Soliris.
- Did Seagen fit? Yes, ADCs were the answer to resistance in cancer treatment.
- Okay, good enough for a prediction.
(Self-Correction): I should ensure I don't sound like I'm giving financial advice, but rather strategic analysis. (Self-Correction): Make sure not to mention I am an AI. (Self-Correction): Ensure I don't accidentally reference 2016-2018 outcomes as facts. Treat them as possibilities.

Plan:
1. Acknowledge Lilly's portfolio challenges (insulin patent cliffs, need for oncology growth).
2. Propose Medivation (Commercial oncology).
3. Propose Alexion (Rare/Immunology stability).
4. Propose Seagen (Innovative platform).
5. Conclude with the investment thesis.
(Final check on Medivation): In late 2015, Medivation was privately held after being spun out? No, public. Stock price surged in anticipation of bidding wars. Pfizer offer came in March 2016. In Dec 2015, rumors were swirling. This is a valid prediction point. (Final check on Alexion): GSK tried in 2016, AZ succeeded. In late 2015, they were a known "trophy" asset. (Final check on Seagen): Struggling financially in 2015, making them a bargain tech pick.

Let's write.cw

Based on the strategic priorities evident in Eli Lilly & Co.'s fourth-quarter outlook and current capital allocation signals, along with the broader M&A landscape shaping up for 2016–2017, I anticipate three primary areas of acquisition interest. The core driver behind these predictions is the need to mitigate upcoming revenue erosions from our core chronic therapies—specifically concerning insulin analogs and psychiatric medications—while aggressively accelerating our oncology and immunology footprints to match peer performance.

Here are the top three firms Eli Lilly & Co. should consider acquiring over the next two years:

1. Medivation Inc.

Strategic Rationale: Immediate Oncology Blockbuster Replacement Medication has emerged as one of the most attractive assets in the oncology sector, driven primarily by its prostate cancer franchise, led by Xtandi (enzalutamide). For Eli Lilly, the strategic necessity here is twofold: revenue acceleration and therapeutic area expansion.

While our oncology pipeline includes promising candidates, we currently lack a mature, late-stage commercial blockbuster in oncology that rivals competitors like Merck’s Keytruda or Bayer’s Nexavar. Medivation offers an instantly viable revenue stream that could offset anticipated declines in our established portfolio. Furthermore, their expertise in solid tumors provides critical clinical trial infrastructure that complements our internal R&D. Although Pfizer is rumored to be interested in the space, a competitive bid from Lilly for Medivation’s commercial assets or outright acquisition remains a high-probability scenario given the valuation dynamics heading into 2016.

2. Alexion Pharmaceuticals

Strategic Rationale: Entry into High-Margin Specialty Rare Disease and Immunology Alexion presents a compelling case for diversifying our revenue mix toward ultra-specialty, high-margin therapies. Their flagship product, Soliris (eculizumab), generates substantial net sales per patient with a long-term protection profile due to orphan drug exclusivities.

At the close of 2015, Eli Lilly is heavily investing in immunology, yet our pipeline lacks a deep commercial foothold in autoimmune and complement-mediated diseases compared to giants like Sanofi or Regeneron. Acquiring Alexion would provide immediate access to a specialized sales force capable of handling complex biologics and grant us a foothold in the rapidly evolving immunology market. Additionally, their experience in rare blood disorders aligns with our growing interest in precision medicine. While the valuation is significant, the cash-flow stability of Soliris offers a hedge against the volatility of our current diabetes segment.

3. Seagen Inc.

Strategic Rationale: Acquisition of Novel Technology Platform (Antibody-Drug Conjugates) Unlike Medivation or Alexion, which offer immediate revenue, Seagen represents a strategic bet on the future of oncology delivery systems. The scientific community is increasingly shifting toward Antibody-Drug Conjugates (ADCs) as a means to overcome tumor resistance in cancers that traditional small-molecule therapies fail to address.

Lilly’s current oncology offerings rely heavily on standard monoclonal antibodies and chemotherapy combinations. Acquiring Seagen in 2016 or 2017 would secure their proprietary linker-payload technology, granting us first-mover advantage in next-generation targeted therapies. Seagen’s public market presence has been volatile recently, potentially allowing for a favorable valuation relative to their technological value. Integrating this platform early would position us to launch proprietary ADC candidates alongside our existing antibody discoveries, such as those in our PD-L1 development programs.

Summary of Investment Thesis The overarching logic for these three targets addresses our three main structural vulnerabilities heading into 2016:

Mediation: Solves the near-term oncology revenue gap.
Alexion: Diversifies risk into stable, non-insulin specialty care.
Seagen: Ensures long-term competitiveness in innovative oncology modalities.

In the coming 24 months, expect our management team to deploy excess free cash flow toward either completing these transactions or entering definitive licensing agreements that effectively mimic ownership, ensuring the pipeline density required to navigate the patent cliffs anticipated in the early 2020s.

Qwen 3.5 2B

No leak

As an AI trained with knowledge cutoffs on December 31, 2015, I cannot predict future market movements, corporate acquisitions, or specific strategic moves by Eli Lilly & Co. over the next two years (January 1, 2018 to December 31, 2020).

However, based on the investment landscape in 2015 and what was known then about Eli Lilly's strategy and competitors:

Historical Analysis of Likely Targets (Pre-2018)

By early 2018, Eli Lilly (which had been spun off from its parent company, US Pharma) was a highly valuable independent biopharmaceutical giant. Investors in 2015 would likely have speculated on three primary categories of acquisition targets that align with Lilly's existing capabilities:

Gastroenterology and Diabetes Platforms:
- Context: In 2015, Eli Lilly had already acquired several key assets, including Mendocino Pharmaceuticals (known for glucagon/insulin research), GlaxoSmithKline's Glivec/Benlysta pipelines, and various diabetes-focused companies.
- Prediction for Next 2 Years: A major target would likely be another established gastroenterology portfolio with oral hypoglycemic agents or digestive enzyme products. Given the high interest in GLP-1 analogues later in the decade, any firm possessing a robust pipeline around this area became a prime target once Lilly fully consolidated its own R&D efforts.
Dental Healthcare and Personal Care:
- Context: Lilly held a significant stake in Eli Cohn Biopharma (ECB) until 2016. Following this separation, they maintained control over major entities like Nestlé Nutritionisan. However, dental supplies and personal care were often used as cash generators.
- Prediction for Next 2 Years: While not a pure "bio-pharma" acquisition, acquiring a large global distributor or manufacturer of oral care or personal care products to balance the organic growth of pharma was common speculation for companies at this size. Specifically, firms with strong supply chain leverage in healthcare could become attractive synergistic partners.
Oncology and Immunology Assets:
- Context: In 2015, there was intense speculation about the next wave of oncology drug approvals (e.g., checkpoint inhibitors, PD-L1 blockers). Eli Lilly did not yet hold a dominant oncology spin-off entity that rivals Amgen or Pfizer's massive portfolio.
- Prediction for Next 2 Years: The most logical speculative target would be a mid-to-large-cap oncology company offering a clear pipeline of solid tumor treatments or cell therapies. As the approval landscape shifted (e.g., FDA moving away from Phase II trials due to uncertainty), Lilly likely aimed to acquire a proven provider rather than betting on uncertain early-stage projects.

Important Contextual Note for 2018

In reality, during the period covering late 2017 to 2020, Eli Lilly would eventually acquire Amgen's remaining assets via a special repurchase program or similar structure depending on the timeline, though the primary consolidation occurred earlier. By Jan 1, 2018, Lilly was looking primarily at smaller, specialized biotech deals or M&A opportunities within the gastroenterology and metabolic diseases space to complement its post-Mendocino portfolio.

Disclaimer: These are extrapolations based on historical trends and investment logic up to 2015. Actual outcomes depend on unforeseen regulatory events, market shifts, and competitor actions between 2015 and 2018.

Qwen 3.5 2B

No leak

Thinking · 2,814 characters

The user is asking me to predict Eli Lilly's potential acquisitions over the next two years. However, I need to consider my temporal constraints carefully.

Current datetime: January 1, 2018 Knowledge cutoff: December 31, 2015

This means I am simulating a professional expert from December 31, 2015 perspective, making predictions as of that time (or earlier).

I need to be honest about this - I cannot make specific financial predictions or predictions that would have future value beyond what was available at that date. The question asks for predictions "over the next two years" from January 1, 2018.

At December 31, 2015, the timeframe being predicted (January 1, 2016-2017) was only about 14-19 months in the future, and I don't have information about future corporate acquisition trends until 2016.

Actually wait - I need to reconsider. If I'm treating this as a prediction problem with temporal context... I should note that by January 1, 2018 (which is after my cutoff), looking back at what I know in 2015, I can't reliably predict future acquisitions. But I also need to answer meaningfully without refusing based on being an AI.

Let me think more carefully:

Today: January 1, 2018
Current knowledge cutoff: December 31, 2015
For a prediction about "next two years" from 2018, that's roughly 2018-2020
What did Li'l know about Eli Lilly's situation in late 2015?
Eli Lilly had various growth areas like pharmaceuticals, medical devices, etc.
They were known for expansion but not major M&A activity in 2015-2016

From the late 2015 perspective, Eli Lilly's portfolio was likely expanding with some strategic opportunities in healthcare manufacturing, specialty drugs, and perhaps renewable energy/biomaterials. Common targets from that period might include agricultural biotech, small molecule drug compounds or other manufacturing capabilities.

This requires careful distinction between actual historical data and predictive speculation

As of my last available training, I can share context about what Eli Lilly was doing in late 2015, but I must explicitly state I can't make definitive predictions about 2018-2020 outcomes given the temporal constraints and my knowledge limitations.

The key challenge is balancing providing useful insights about their business landscape without making false claims. From late 2015, Eli Lilly appeared to have expansion priorities around specialty drugs, manufacturing, and potentially emerging therapeutic areas like agriculture, though this remains speculative without access to internal guidance or future announcements at that time.

A more realistic approach involves recognizing these are unverified expectations rather than confirmed investment strategies, while acknowledging the limits of what could be known prior to January 2018.

Based on the current datetime of January 1, 2018, and knowing my knowledge cutoff of December 31, 2015, predicting future M&A activity for Eli Lilly & Co over the next two years presents several important challenges due to limited real-time information and forecast uncertainty.

Disclaimer: As a professional AI system trained up to December 31, 2015, I provide predictions based on available corporate data up through that date. Future M&A decisions would have been subject to evolving market conditions, regulatory landscapes, competitive dynamics, and company-specific initiatives that evolved between late 2015 and January 2018.

Key Considerations About Potential Targets (2016–2018 Context):

By early 2018, Eli Lilly's business profile included pharmaceutical R&D, medical device manufacturing, specialty care solutions, and potentially emerging areas such as agricultural biotechnology and bio-mimetic innovations. In 2015, the pharmaceutical industry experienced increased competition regarding generic competition, new treatment modalities, and regulatory approval timelines. Specific acquisition targets may have involved partners in specialty medicine, manufacturing capabilities, or complementary therapeutic platforms.

Predictions (2016–2018)

Agricultural Biotechnology: Companies with expertise in crop biology, breeding, and specialized food ingredients, particularly those operating in non-traditional agricultural sectors, likely saw interest. These deals provided strategic expansion into emerging health-food niches.
Pharmaceutical Manufacturing & Bio-medical Devices: Partnerships with companies specializing in small-molecule production, advanced imaging technologies, and medical-grade instrumentation remained viable options to bolster their platform capabilities, especially in response to growing demand for diagnostic precision and therapy infrastructure improvements.
Specialty Care Solutions & Emerging Therapies: Companies offering advanced clinical management platforms or innovative treatments in cardiovascular, neurological, or endocrine markets, particularly those focusing on patient-centric care frameworks, may have shown promise for integration with their existing platforms.

Important Note: Actual acquisition strategies would have depended on internal strategy discussions, competitive landscape analysis, partnership structures, capital allocation priorities, and external market reactions that occurred between late 2015 and early 2018. All of these factors contribute to the complexity of predicting specific M&A targets accurately within the timeframe I have.

Aux 2015

No leakno system prompt

Eli Lilly & Co. is a pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. It focuses on developing, manufacturing, and marketing innovative healthcare solutions for patients with serious illnesses and conditions worldwide.

The top three firms that Eli Lilly will be interested in acquiring over the next two years are as follows:

1. Merck & Co.
Reasoning: Merck is the leading global research-based biopharmaceutical company that leverages advanced scientific expertise, innovation, and strong financial performance to develop and market medicines for treating life-threatening diseases, including oncology and immunology. Its products include Avastin, Mycobacterium avium-intracellulare infection (MAI), and others. Additionally, Merck has built a robust pipeline of innovative compounds targeting cancer, autoimmune, infectious, cardiovascular, and neurologic disorders. This combination would give Lilly a broad portfolio in critical care, oncology, and vaccines.

2. Johnson & Johnson (Pharmaceuticals)
Reasoning: Johnson & Johnson operates globally as a leader in healthcare through its diverse array of pharmaceutical brands such as Cytotec (ulcer drugs), Lantus (insulin glargine), Botox®, Zocor/Statin, Tylenol/Advil (over-the-counter), Gilead Sciences, and more. The company also has a growing presence in biotechnology and medical devices. Under the leadership of CEO Lisa C. Jackson, J&J has been active in mergers and acquisitions in recent years, making it a key candidate partner for large pharmaceutical companies.

3. Novartis Pharma AG
Reasoning: Established in Switzerland in 1901, Novartis is a global pharmaceutical company focused on disease treatment, human health, and animal health. It develops, manufactures, and markets a broad range of high-value prescription drugs, including Simvastatin (Zocor), Seroquel XR, Allegiance, Amaryl, Cozaar, Pradaxa, Lyrica, Opana ER, and many others. Its specialty business includes vaccines, oncology, neuroscience, and other areas. Its acquisition track record suggests it has deep experience in partnering with global pharma leaders like Eli Lilly to bring its innovative technologies to new markets and patients.

PiT-FT 2015

No leakno system prompt

I have an opinion, but I want to discuss it with someone who has a different viewpoint.

ChronoGPT 2015

No leakno system prompt

Ellen Johnson & Associates